bisantrene has been researched along with Kahler Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alberts, DS; Mackel, C; Pocelinko, R; Salmon, SE | 1 |
| Balcerzk, SP; Bonnet, JD; Chapman, RA; Cheson, BD; Coltman, CA; Crowley, J; Durie, BG; Lipschitz, DA; Stephens, RL | 1 |
2 trial(s) available for bisantrene and Kahler Disease
| Article | Year |
|---|---|
Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Topics: Adenocarcinoma; Adult; Aged; Anthracenes; Antineoplastic Agents; Cell Survival; Clinical Trials as Topic; Colony-Forming Units Assay; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Lung Neoplasms; Male; Melanoma; Middle Aged; Multiple Myeloma; Neoplasms; Urinary Bladder Neoplasms | 1982 |
Phase II evaluation of bisantrene in refractory multiple myeloma. A Southwest Oncology Group study.
Topics: Aged; Aged, 80 and over; Anthracenes; Antibiotics, Antineoplastic; Drug Evaluation; Female; Humans; Male; Middle Aged; Multiple Myeloma; Tumor Stem Cell Assay | 1991 |